| Resistance | Susceptibility | Intermediate susceptibility | |
| Group 1: first-line oral agents | |||
| Isoniazid | 17 (100) | ||
| Ethambutol | 14 (82.4) | 2 (11.8) | 1 (5.9) |
| Rifampicin | 17 (100) | ||
| Pyrazinamide | 9 (53) | 8 (47) | |
| Rifabutin | 13 (76.5) | 3 (17.6) | 1 (5.9) |
| Group 2: injectable anti-TB medication | |||
| Amikacin | 7 (41.2) | 10 (58.8) | |
| Kanamycin | 2 (11.8) | 4 (23.5) | |
| Streptomycin | 15 (88.2) | 2 (11.8) | |
| Capreomycin | 5 (29.4) | 10 (58.8) | |
| Group 3: fluoroquinolones | |||
| Ofloxacin | 1 (5.9) | ||
| Moxifloxacin | 3 (17.6) | 13 (76.5) | 1 (5.9) |
| Ciprofloxacin | 4 (23.5) | 12 (70.6) | |
| Group 4: other bacteriostatic second-line agents | |||
| Protionamide | 4 (23.5) | 12 (70.6) | |
| Cycloserine | 1 (5.9) | 7 (41.2) | |
| Group 5: anti-TB drugs with unclear efficacy | |||
| Linezolid | 13 (76.5) | 3 (17.6) | |
| Clofazimine | 11 (64.7) | ||
| Clarithromycin | 2 (11.8) | 5 (29.4) | |
| Augmentin | 9 (53) | 4 (23.5) | |
| Imipenem | 2 (11.8) | ||
| Others | |||
| Co-trimoxazole | 4 (23.5) | 13 (76.5) | |
| Ertapenem | 7 (41.2) | ||
| Tigecycline | 7 (41.2) | 1 (5.9) | |
| Meropenem | 1 (5.9) | ||
Data are presented as n (%).